Key facts
- Pathfinder Bio’s last known valuation is $1.3M (Mar 2025).
- It has raised $730K.
- Notable investors include Innovate UK, SFC Capital, ICURe, Oxford Technology Management, biotope by VIB.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Pathfinder Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Pathfinder Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Pathfinder Bio
Developer of an enzyme discovery and improvement technology platform designed for sustainable biomanufacturing. The company's platform uses a proprietary deep-tech laboratory setup that enables measurement of enzyme performance through engineered bacterial cells competing at scale, sifting through billions of enzyme variants in a single reaction while generating vast amounts of high quality data to rapidly design optimal enzyme based processes, enabling manufacturers in cosmetics, fragrances, fine chemicals and broader circular bioeconomy sectors to deploy efficient, scalable and eco-friendly production methods.
- Sector
- Materials and Resources
- HQ
- Nottingham, United Kingdom
- Founded
- 2022
- Employees
- 3
- Website
- pathfinderbio.co.uk/
- Ownership
- Privately Held (backing)
Pathfinder Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Pathfinder Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Pathfinder Bio in its N-PORT filings yet. We sweep new filings monthly.